ReviewExperimental brain research2009
Mode of action of cannabinoids on nociceptive nerve endings.
Review in Experimental brain research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 50 citations in OpenAlex.
- Review
- Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CBPharmacological reports : PR · 2021Review
- Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain.Brain and behavior · 2020Article
- Tingenone, a pentacyclic triterpene, induces peripheral antinociception due to cannabinoid receptors activation in mice.Inflammopharmacology · 2018Article
- Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.European journal of pain (London, England) · 2016Article
- [Pharmacological aspects of pain research in Germany].Schmerz (Berlin, Germany) · 2015Review
- Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis.Arthritis research & therapy · 2015Review
- JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.Pharmacological research · 2014Article
- Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.European journal of pharmacology · 2014Article
- CB1 cannabinoid receptor agonist prevents NGF-induced sensitization of TRPV1 in sensory neurons.Neuroscience letters · 2013Article
- The antinociceptive and antihyperalgesic effects of topical propofol on dorsal horn neurons in the rat.Anesthesia and analgesia · 2013Article
- GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination.PloS one · 2013Article
- Differences in peripheral endocannabinoid modulation of scratching behavior in facial vs. spinally-innervated skin.Neuropharmacology · 2012Article
- Update on peripheral mechanisms of pain: beyond prostaglandins and cytokines.Arthritis research & therapy · 2011Review
- Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells.Experimental eye research · 2010Article
- CB2: a cannabinoid receptor with an identity crisis.British journal of pharmacology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, cannabinoids have emerged as attractive alternatives or supplements to therapy for chronic pain states. However, in humans the activation of cannabinoid receptors in neurons of the central nervous system is associated with psychotropic side effects, temporary memory impairment and dependence, which arise via the effects of cannabinoids on forebrain circuits. For clinical exploitation of the analgesic properties of cannabinoids, a major challenge is to devise strategies that reduce or abolish their adverse effects on cognitive, affective and motor functions without attenuating their analgesic effects. The cannabinoid receptor family currently includes two cloned metabotropic receptors: CB1, CB2 and possibly GPR55 which are distributed widely across many key loci in pain-modulating pathways, including the peripheral terminals of primary afferents. Modulation of transducer ion channels expressed at nociceptive terminals occurs upon activation of metabotropic cannabinoid receptors, but direct cannabinoid action on ion channels involved in sensory transduction or regulation of neuron excitability likely contributes to the peripheral cannabinoid effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.